Technology ID
TAB-5140
D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders
E-Numbers
E-146-2016-0
E-146-2016-1
Lead Inventor
Sibley, David
Lead IC
NINDS
Co-Inventors
Marugan, Juan
Free, Benjamin
Moritz, Amy
Aube, Jeffrey
Steiner, Joseph
Frankowski, Kevin
Ferrer-Alegre, Marc
Southall, Noel
Xu, Xin
Weiner, Warren
ICs
NINDS
NCATS
Applications
Therapeutics
Therapeutic Areas
Neurology
Development Stages
Pre-clinical (in vivo)
Every major dopaminergic therapy on the market today shares the same fundamental limitation: it cannot distinguish between two closely related receptor subtypes (D2 and D3). This technology changes that.
We have discovered and optimized a novel small molecule, ML417, that selectively activates the D3 dopamine receptor while leaving its close cousin, the D2 receptor, untouched. While primarily positioned for Parkinson's Disease and Restless Legs Syndrome, the D3-selective profile and strong brain penetrance demonstrated by this scaffold open high-value pipeline expansion opportunities in broader neurological and neuropsychiatric indications, including substance use disorders, schizophrenia, and cognitive decline.
Commercial Applications
- Current FDA-approved dopamine agonists work by activating both D2 and D3 receptors together, since the two are nearly indistinguishable at the molecular level. This lack of selectivity comes at a massive cost: patients on these medications frequently develop severe impulse control disorders (compulsive gambling, shopping, and hypersexuality)—serious, life-altering side effects tied specifically to D2 activation that limit physician dosing confidence.
By contrast, D3-selective activation preserves the desired therapeutic effects (including motor symptom relief and neuroprotection) without triggering the D2-driven side effects that destroy patient quality of life.
- The Market: Parkinson's Disease alone carries an estimated $14.4 billion annual economic burden in the U.S. The Opportunity: A partner collaborating on this platform has the unique strategic opportunity to replace imprecise, standard-of-care drugs (like pramipexole and ropinirole) with a safer, highly tolerated, next-generation therapeutic class.
Competitive Advantages
- Our lead compound, ML417, represents a meaningful advance in a field where "selective" has historically only meant modest improvement.
Superior Selectivity Profile: In head-to-head comparisons, ML417 outperforms the most selective D3 agonists previously reported in scientific literature, leaving the D2 receptor virtually untouched.
- Demonstrated Neuroprotection: In preclinical models, our compound demonstrated stronger neuroprotective activity than pramipexole, one of the most widely prescribed D3-preferring drugs on the market today. Robust, De-Risked Foundation: The platform emerged from a systematic medicinal chemistry campaign spanning over 100 synthesized analogs. It features confirmed selectivity across multiple orthogonal assays, favorable early pharmacokinetic signals (including excellent brain penetrance), and a clean genetic toxicity profile. Secured Intellectual Property: Issued US and EP patents, offering a clean, proprietary runway for clinical development.
Licensing Contact: